Identification of Optimal Mouse Models of Systemic Sclerosis by Interspecies Comparative Genomics
Objective Understanding the pathogenesis of systemic sclerosis (SSc) is confounded by considerable disease heterogeneity. Animal models of SSc that recapitulate distinct subsets of disease at the molecular level have not been delineated. We applied interspecies comparative analysis of genomic data f...
Saved in:
Published in | Arthritis & rheumatology (Hoboken, N.J.) Vol. 68; no. 8; pp. 2003 - 2015 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.08.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objective
Understanding the pathogenesis of systemic sclerosis (SSc) is confounded by considerable disease heterogeneity. Animal models of SSc that recapitulate distinct subsets of disease at the molecular level have not been delineated. We applied interspecies comparative analysis of genomic data from multiple mouse models of SSc and patients with SSc to determine which animal models best reflect the SSc intrinsic molecular subsets.
Methods
Gene expression measured in skin from mice with sclerodermatous graft‐versus‐host disease (GVHD), bleomycin‐induced fibrosis, Tsk1/+ or Tsk2/+ mice was mapped to human orthologs and compared to SSc skin biopsy–derived gene expression. Transforming growth factor β (TGFβ) activation was assessed using a responsive signature in mice, and tumor necrosis factor receptor superfamily member 12A (TNFRSF12A) expression was measured in SSc patient and mouse skin.
Results
Gene expression in skin from mice with sclerodermatous GVHD and bleomycin‐induced fibrosis corresponded to that in SSc patients in the inflammatory molecular subset. In contrast, Tsk2/+ mice showed gene expression corresponding to the fibroproliferative SSc subset. Enrichment of a TGFβ‐responsive signature was observed in both Tsk2/+ mice and mice with bleomycin‐induced skin fibrosis. Expression of TNFRSF12A (the TWEAK receptor/fibroblast growth factor–inducible 14) was elevated in skin from patients with fibroproliferative SSc and the skin of Tsk2/+ mice.
Conclusion
This study reveals similarities in cutaneous gene expression between distinct mouse models of SSc and specific molecular subsets of the disease. Different pathways underlie the intrinsic subsets including TGFβ, interleukin‐13 (IL‐13), and IL‐4. We identify a novel target, Tnfrsf12a, with elevated expression in skin from patients with fibroproliferative SSc and Tsk2/+ mice. These findings will inform mechanistic and translational preclinical studies in SSc. |
---|---|
Bibliography: | Supported by the Scleroderma Research Foundation (grants to Drs. Aliprantis, Varga, and Whitfield), the NIH (grant R01‐AR‐061384‐01 to Drs. Artlett, Blankenhorn, and Whitfield, and grants 2R01‐AR‐051089 and P30‐AR‐061271 to Dr. Lafyatis), and the US Department of Defense (grant PR100338 to Drs. Artlett, Blankenhorn, and Whitfield). Drs. Sargent and Li contributed equally to this work. Dr. Whitfield has filed patent applications for biomarkers in systemic sclerosis and is the scientific founder of Celdara Medical LLC. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
ISSN: | 2326-5191 2326-5205 2326-5205 |
DOI: | 10.1002/art.39658 |